reading time

AVCT Share Price

Avacta Group plc is a biotechnology company that focuses on the discovery and development of novel cancer therapies and diagnostics. The company was founded in 2004 and is headquartered in Wetherby, UK.

Avacta has several programs in development, including AVA004, a PD-L1 inhibitor for the treatment of solid tumors; AVA6000, a drug conjugate for HER2-positive breast cancer; and AVA-Trap, a diagnostic test for COVID-19.

AVCT Share Price Value

The London Stock Exchange has the Avacta Group listed on the AIM market under the ticker symbol “AVCT.” The AIM market caters to smaller, growing companies as a sub-market of the London Stock Exchange. In addition, AVCT Share Price is currently at 120 GBp as of this post.

Avacta Group’s listing on the AIM market gives the company access to capital markets and a broad range of potential investors. In addition, as a publicly traded company, Avacta must comply with various regulatory requirements and disclose information about its financial performance and operations to investors.

Brief Background of AVCT

A biotechnology company based in the UK, Avacta Group specializes in developing novel immunotherapies and diagnostics using its proprietary Affimer technology. Small proteins called Affimers can be engineered to bind to a wide range of molecular targets. Thus, making them useful for various applications in healthcare and other industries.

The company’s pipeline includes multiple drug candidates for cancer treatment and a range of diagnostic tests for conditions such as COVID-19 and various cancers. Avacta also offers contract research services to other companies in the life sciences industry.

Founded in 2004, Avacta became a publicly traded company in 2006. Its shares are listed on the London Stock Exchange’s AIM market. As of September 2021, the company had a market capitalization of approximately £450 million.

Advantages of Investing in AVCT

Here are some potential advantages of investing in Avacta Group:

  1. Innovative Technology. Avacta Group is a biotechnology company specializing in developing innovative technologies and products for the healthcare sector. Their core technology platform, Affimer, is a next-generation protein scaffold with significant advantages over traditional antibodies.
  2. Strong Pipeline. Avacta has a strong pipeline of product candidates across various therapeutic areas, including oncology, immunology, and infectious diseases. In addition, the company has multiple partnerships and collaborations with leading biopharmaceutical companies to develop and commercialize its products.
  3. COVID-19 Testing. Avacta has developed a rapid COVID-19 antigen test using its Affimer technology. The test has shown high accuracy in clinical studies and has the potential to be used as a screening tool for large populations. The company is also developing COVID-19 therapeutics using its Affimer technology.
  4. Experienced Management Team. Avacta has an experienced management team with a track record of success in the biotechnology industry. The team has significant expertise in product development, regulatory affairs, and commercialization.
  5. Potential for Growth. The biotechnology sector is expected to multiply in the coming years, driven by increasing demand for innovative healthcare solutions. Avacta is well-positioned to benefit from this trend with its innovative technology platform and a robust pipeline of product candidates.

AVCT Competitors

Avacta Group operates in the biotechnology sector, a highly competitive industry with many companies operating in different market areas. Some of Avacta Group’s competitors in the stock market include:

  1. Abcam PLC (ABC). Abcam is a leading supplier of protein research tools and services for life science research.
  2. Bio-Rad Laboratories, Inc. (BIO). Bio-Rad is a global leader in developing, manufacturing, and marketing life science research products and clinical diagnostics.
  3. GenScript Biotech Corporation (GNS). GenScript is a leading biotechnology company that provides gene synthesis, peptide synthesis, and antibody development services.
  4. Moderna, Inc. (MRNA). Moderna is a biotechnology company that develops mRNA-based therapeutics and vaccines.
  5. Regeneron Pharmaceuticals, Inc. (REGN). Regeneron is a biopharmaceutical company that develops and commercializes medicines to treat severe medical conditions.
  6. Roche Holding AG (ROG). Roche is a global healthcare company that develops and commercializes pharmaceuticals and diagnostics products.

The Best Copytrading Platform

eToro UK
Minimum deposit 200 USD
Regulated in Europe
Trade selections Forex, Crypto, Stocks, Commodities, ETFs, Indices
  • Zero Commissions on Trades

  • CopyPortfolios/Copytrade Feature

  • Ask Experts Questions

  • Wide Range of Stocks


Avacta is a promising biotechnology company with a unique technology platform and a strong focus on developing novel cancer therapies and diagnostics. However, as with any biotech company, there are inherent risks and uncertainties associated with drug development and commercialization, and investors should carefully consider these factors before investing in Avacta’s stock.


FAQ: AVCT Share Price

Does AVCT pay dividends?

Avacta Group had not yet paid any dividends to its shareholders.

How much money does AVCT make?

According to the Avacta Group's financial statements for the year ended 31 July 2021, the company reported a revenue of £6.0 million (GBP). However, it's important to note that this figure can fluctuate over time and may not be indicative of the company's future performance. It's also worth mentioning that companies often report revenue figures net of any discounts, allowances, and returns, so the actual amount of money received by the company may be different.

What is the historic performance of this stock?

In its 2021 fiscal year, Avacta Group reported revenue of £6.0 million (GBP), up from £5.3 million in the previous year. The company also reduced its net loss from £22.1 million in 2020 to £13.8 million in 2021.

Over the past five years, Avacta Group has experienced significant revenue growth. For example, in 2016, the company reported revenue of just £2.6 million (GBP).

However, it's worth noting that Avacta Group has also incurred significant losses over the past few years as it invests in research and development and commercialization activities. As of July 31, 2021, the company lost £116.4 million (GBP).

Despite these losses, Avacta Group has received significant investments from institutional investors and has formed partnerships with major pharmaceutical companies, which demonstrates confidence in the company's long-term prospects.

Overall, Avacta Group's historical performance has been characterized by solid revenue growth and significant investment in R&D and commercialization, leading to losses. However, the company has formed strategic partnerships and attracted significant investment, suggesting investors are optimistic about its prospects.

Rate this post
Simon Williams
Latest posts by Simon Williams (see all)